10mg/ml

Adriblastina

Adriblastina Injection 10mg

Doxorubicin

Pfizer Laboratories (Pvt) Ltd.

Drug Identity

Active Ingredient
Doxorubicin
Drug Class
Cancer
ATC Code
L01DB01
Status
Essential Medicine

How It Works

Administer IV push over 1-2 min or IVP Bolus. Infusion via central venous line recommended. Reconstitute lyophilized powder with NS to a final concentration of 2 mg/ml as follows. Further dilution in D5W or NS is stable for 48 hours at room temperature (25-C) when pro-tected from light. Unstable in solutions with a pH < 3 or > 7.Standard IV Dilution: IVP: Dose/syringe (concentration: 2 mg/ml). IVP Bolus: Dose 50-100 ml D5W or NS.

How to Take It

Dosage information not available for this product.

Safety Alerts

Patients with marked myelosuppression, stomatitis

Important Warnings

Hematological monitoring re-quired, Cardiac disease, caution in handling
irritant to tissues, elderly, hypertension, previous myocardial irradiation

Side Effects

Dehydrationdiarrhoeared colouration of the urinealopeciabone-marrow suppressioncardiomyopathy (with higher cumulative doses)extravasationheart failurehyperuricaemianauseaoral mucositisrenal damagethromboembolismtumourlysis Syndromevomiting

Drug Interactions

Heparin.

Pregnancy & Lactation

Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding

Price Intelligence

Rs 1,051.85
DRAP approved maximum price · per unit · approved 01 Jul, 2024
No retail price observed for this pack. Retailers may not exceed the approved maximum.
Prices across sources
No retail prices recorded

Should you consider an alternative?

Other options containing Doxorubicin, and what they are not.

For pharma professionalsCompany, market and opportunity intelligence

Company

254
brands
273
molecules
6
alerts

Prices as of 30 July 2026 · DRAP ceiling as of 30 July 2026 · schema v3-SKU

For medicine intelligence and professional reference only. Not medical advice.